Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.

Yan S, Yang H, Wang Y, Zhu L, Wang B, Zhang L, Hao Q

Open source

DOI
10.3390/ph19091393
Published
2026 Sep 2
Container
Pharmaceuticals (Basel, Switzerland)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ph19091393,
  title = {Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.},
  author = {Yan S and Yang H and Wang Y and Zhu L and Wang B and Zhang L and Hao Q},
  year = {2026},
  journal = {Pharmaceuticals (Basel, Switzerland)},
  doi = {10.3390/ph19091393},
  url = {https://doi.org/10.3390/ph19091393}
}

RIS

TY  - JOUR
TI  - Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.
AU  - Yan S
AU  - Yang H
AU  - Wang Y
AU  - Zhu L
AU  - Wang B
AU  - Zhang L
AU  - Hao Q
PY  - 2026
JO  - Pharmaceuticals (Basel, Switzerland)
DO  - 10.3390/ph19091393
UR  - https://doi.org/10.3390/ph19091393
ER  - 

APA

S, Y., H, Y., Y, W., L, Z., B, W., L, Z., & Q, H. (2026). Flavonoids for MASLD: Hepatic Lipid Targets, Biopharmaceutic Barriers, and Formulation Strategies.. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph19091393

Source records